Tenon Medical Inc TNON Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.64 unchanged at close Nov 6
Last close · Previous close $1.64
- Market cap
- $542.30KAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$1.64down $2.08, 55.85%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.64Nov 5
- Volume91.80KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume149.12KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.57 to $45.50; now $1.64
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
TNON trailed the S&P 500 in all 5 periods.
| Period | TNON and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | TNON: down 55.9% S&P 500: down 5.6% | TNON trailed the S&P 500 by 50.3 percentage points Trailed |
| 3M | TNON: down 72.1% S&P 500: down 4.1% | TNON trailed the S&P 500 by 68.0 percentage points Trailed |
| YTD | TNON: down 95.1% S&P 500: up 8.7% | TNON trailed the S&P 500 by 103.8 percentage points Trailed |
| 1Y | TNON: down 95.9% S&P 500: up 10.9% | TNON trailed the S&P 500 by 106.8 percentage points Trailed |
| Long term | ||
| 3Y | TNON: down 99.7% S&P 500: up 75.0% −85.7% vs +20.5% a year | TNON trailed the S&P 500 by 174.7 percentage points Trailed |
$10,000 invested in TNON a year ago (Nov 6, 2025) would be worth about $407 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $11,088.
TNON trailed the S&P 500 in all 5 periods.
| Period | TNON and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | TNON: down 55.9% S&P 500: down 5.6% | TNON trailed the S&P 500 by 50.3 percentage points Trailed |
| 3M | TNON: down 72.1% S&P 500: down 4.3% | TNON trailed the S&P 500 by 67.8 percentage points Trailed |
| YTD | TNON: down 95.1% S&P 500: up 7.8% | TNON trailed the S&P 500 by 102.9 percentage points Trailed |
| 1Y | TNON: down 95.9% S&P 500: up 9.7% | TNON trailed the S&P 500 by 105.6 percentage points Trailed |
| Long term | ||
| 3Y | TNON: down 99.7% S&P 500: up 68.8% −85.7% vs +19.1% a year | TNON trailed the S&P 500 by 168.5 percentage points Trailed |
$10,000 invested in TNON a year ago (Nov 6, 2025) would be worth about $407 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,969.
All-time high
$139,440.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Apr 27, 2022.
Stock splits
3
Latest: 1-for-35 on . Share counts adjust after each split.
All 3 splits
- 1-for-35
- 1-for-8
- 1-for-10
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- 0.1×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −2,226.64%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $4.49MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own TNON DCF in Excel. Value Tenon Medical with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $5.31Mup 80.3%
- Net income
- −$13.70M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $887.00K | −$3.18M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $770.00K | −$3.09M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $726.00K | −$3.62M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $564.00K | −$2.77M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $1.17M | −$3.34M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $1.48M | −$2.83M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $1.38M | −$3.48M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $1.28M | −$4.05M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $160.00K | −$7.05M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $691.00K | −$18.92M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $2.93M | −$15.58M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $3.28M | −$13.67M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $3.94M | −$12.56M | Paused See the note under the price. |
Margins
- Gross 66.8%
- Operating −242.7%
- Net −257.9%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$12.08MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$11.77MLast 12 months
- Capital spending$309.00KLast 12 months
- −227.3%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $2.85MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $1.73MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$5.68MAs of Jun 30, 2026
- Net debt$3.95MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 0.58As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −548.4%Last 12 months
Over the last 12 months, Tenon Medical lost money: its net loss was 548.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −124.8%Last 12 months
Over the last 12 months, Tenon Medical’s net loss was 124.8% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Tenon Medical Inc
Tenon Medical, Inc. is a medical device company founded in 2012 and committed to developing novel technologies for patients suffering from debilitating SI joint pain and dysfunction. The Company markets the Catamaran ® and SImmetry+ ® SI Joint Fusion Systems, which offer a novel, less invasive approach to treating SI joint disease. Together, these platforms uniquely position Tenon with multiple surgical approaches, lateral and inferior-posterior, both designed to be minimally invasive, enable authentic arthrodesis, and supported by robust clinical evidence, including the published prospective Mainsail ™ and EVoluSIon ™ SI joint fusion studies. These differentiated technologies enable physicians to customize treatment plans through an innovative portfolio spanning SI joint fusion, spinal fusion, and deformity adjuncts, each solution engineered to deliver fusion outcomes more reliably. This multi-platform, multiapproach strategy strengthens Tenon's competitive advantage in the expanding SI joint fusion market and underscores the Company's commitment to delivering proven, durable outcomes for physicians and patients. Tenon is focused on three commercial opportunities in the SI joint market: 1) primary SI joint procedures, 2) revision of failed SI joint implants, and 3) augmenting spinal fusion.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
TNON news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
TNON stock FAQ
What is TNON stock’s price today?
Tenon Medical (TNON) traded at $1.64 at the close on , unchanged from the previous close of $1.64. Over the past 52 weeks it has traded between $1.57 and $45.50.
What is Tenon Medical’s market cap?
Tenon Medical’s market capitalization is about $542.3 thousand. That’s Tiingo’s daily market cap for , at that day’s closing price of $1.64 (how market cap works).
How much revenue does Tenon Medical make?
Tenon Medical reported $5.3 million of revenue over the four quarters to , up 80.3% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $1.3 million, up 126.8% from a year earlier.
Is Tenon Medical profitable?
Not over the four quarters to . Tenon Medical reported a net loss of $13.7 million across those four quarters on $5.3 million of revenue.
Does TNON pay a dividend?
Tenon Medical hasn’t paid a dividend in the last twelve months.
What is TNON’s 52-week high and low?
Over the past 52 weeks TNON has traded as low as $1.57 and as high as $45.50. At $1.64 at the close on , it is 96.4% below that high and 4.5% above the low.
What is TNON’s all-time high?
TNON’s highest closing price was $139,440.00 on , adjusted for stock splits. At $1.64 at the close on , it is 100.0% below that record.
Has TNON stock ever split?
Yes, three times: 1-for-10 on ; 1-for-8 on ; 1-for-35 on .
How has TNON stock performed?
Including dividends and measured to the close on , TNON has returned −95.1% so far this year and −95.9% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.7% and +10.9%. Past performance doesn’t predict future returns.
What sector and industry is Tenon Medical in?
Tenon Medical is in the Healthcare sector and the Medical Devices industry, and is headquartered in California, USA.
What exchange does TNON trade on?
Tenon Medical trades on the Nasdaq under the ticker symbol TNON. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.